Heart attack patients get early cholesterol drug in landmark trial
NCT ID NCT07290699
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a powerful cholesterol-lowering drug (recaticimab) early after a heart attack can safely reduce future heart problems. About 2,442 adults who recently had a heart attack will receive the drug or standard care. The goal is to see if this approach lowers cholesterol, controls inflammation, and prevents major heart events like another heart attack or stroke.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSTEMI - NON-ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (MI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive chest pain registry reveals gaps between guidelines and real-world care in china
- Simple arm cuff before angioplasty may boost heart attack recovery
- Suction device may improve outcomes in heart attack patients with large clots
- AI blood test could spot heart attacks faster
- Heart attack patients may benefit from Clot-Busting drug before delayed procedure
- Heart attack patients to receive injectable gel that may limit damage